Your browser doesn't support javascript.
loading
Association Between Previous or Active Cancer and Clinical Outcomes in TAVR Patients: A Systematic Review and Meta-Analysis of 255,840 Patients.
Diaz-Arocutipa, Carlos; Torres-Valencia, Javier; Zavaleta-Camacho, Gabriela; Vicent, Lourdes.
Afiliação
  • Diaz-Arocutipa C; Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
  • Torres-Valencia J; Programa de Atención Domiciliaria - EsSalud, Lima, Peru.
  • Zavaleta-Camacho G; Departamento de Cardiología, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
  • Vicent L; Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Lima, Peru.
Front Cardiovasc Med ; 8: 763557, 2021.
Article em En | MEDLINE | ID: mdl-34796218
Background: It has been proposed that transcatheter aortic valve replacement (TAVR) may be an option for patients with cancer and severe aortic stenosis. We assessed the association between previous or active cancer and clinical outcomes in TAVR patients. Methods: We searched four electronic databases from inception to March 05, 2021. The primary outcome was all-cause mortality. Secondary outcomes were cardiovascular mortality, myocardial infarction, stroke, acute kidney injury, pacemaker implantation, major bleeding, and vascular complications. All meta-analyses were performed using a random-effects model. Relative risks (RRs) and adjusted hazard ratios (aHRs) with their 95% confidence interval (95% CI) were pooled. Results: Thirteen cohort studies involving 255,840 patients were included. The time period for mortality ranged from inpatient to 10 years. Patients with active cancer had a higher risk of all-cause mortality using both crude (RR, 1.46; 95% CI, 1.13-1.88) and adjusted (aHR, 1.79; 95% CI, 1.43-2.25) estimates compared to non-cancer group. In contrast, the risk of cardiovascular mortality (RR, 1.26; 95% CI, 0.58-2.73), myocardial infarction (RR, 0.94; 95% CI, 0.34-2.57), stroke (RR, 0.90; 95% CI, 0.75-1.09), pacemaker implantation (RR, 0.87; 95% CI, 0.50-1.53), acute kidney injury (RR, 0.88; 95% CI, 0.74-1.04), major bleeding (RR, 1.15; 95% CI, 0.80-1.66), and vascular complications (RR, 0.96; 95% CI, 0.79-1.18) was similar between patients with or without cancer. Conclusion: Our review shows that TAVR patients with active cancer had an increased risk of all-cause mortality. No significant association with secondary outcomes was found.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Front Cardiovasc Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Peru País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Front Cardiovasc Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Peru País de publicação: Suíça